公开(公告)号：US09925134B2

公开(公告)日：2018-03-27

申请号：US11803805

申请日：2007-05-16

Applicant: Delphine Rival ,  Sebastien Bonnet ,  Isabelle Orly ,  Eric Perrier

Inventor： Delphine Rival ,  Sebastien Bonnet ,  Isabelle Orly ,  Eric Perrier

IPC: A61K36/185 ,  A61K8/97 ,  A61K36/31 ,  A61K36/8998 ,  A61Q19/00 ,  G01N33/557 ,  A61Q1/06 ,  A61Q5/02 ,  A61Q19/04 ,  A61Q19/08 ,  A61Q19/10

CPC classification number: A61K8/97 ,  A61K36/185 ,  A61K36/31 ,  A61K36/8998 ,  A61K2800/91 ,  A61Q1/06 ,  A61Q5/02 ,  A61Q19/00 ,  A61Q19/04 ,  A61Q19/08 ,  A61Q19/10 ,  G01N33/557 ,  G01N2333/503 ,  G01N2500/04

Abstract: The invention relates to substances which are capable of protecting FGF-2, to a composition for preventing or controlling degradation of FGF-2, and a method of protecting FGF-2 in the skin from degradation.In particular, the invention relates to an extract of Hibiscus Abelmoschus or ambrette, a rebokza extract, a gougizi berry extract, a banha extract, a lessonia extract, a mustard flour extract, a wooyin extract, a barley extract, and/or a sesame extract, in amounts effective to protect FGF-2 from its degradation.Further, the present invention allows the extracellular matrix to be restructured, particularly at the dermis, which is useful, for example, for controlling aging.

公开(公告)号：US20090081783A1

公开(公告)日：2009-03-26

申请号：US11897617

申请日：2007-09-01

Applicant: Nicolas Bechetoille ,  Valerie Andre ,  Isabelle Orly ,  Eric Perrier

Inventor： Nicolas Bechetoille ,  Valerie Andre ,  Isabelle Orly ,  Eric Perrier

IPC: C12N5/08

CPC classification number: C12N5/0639 ,  C12N5/064 ,  C12N5/0697 ,  C12N5/0698 ,  C12N2502/091 ,  C12N2502/094 ,  C12N2502/097 ,  C12N2502/1121 ,  C12N2502/1323 ,  C12N2502/243 ,  C12N2502/28 ,  C12N2503/06

Abstract: The present invention relates to a method for preparing Langerhans cells or interstitial dendritic cells, or both, from CD14+ monocytes stemming from the peripheral circulatory blood of a living being, wherein the method comprises differentiation of CD14+ monocytes into either Langerhans cells, interstitial dendritic cells, or into both types of cells by placing the CD14+ monocytes in the presence of a cell environment comprising epithelial cells and/or mesenchymatous cells.The present invention also relates to cell or tissue models comprising such prepared Langerhans cells and/or interstitial dendritic cells, and optionally macrophages and endothelial cells, and to the uses of such cell or tissue models.

Abstract translation: 本发明涉及从活体的外周循环血中产生的CD14 +单核细胞制备朗格汉斯细胞或间质树突状细胞或两者的方法，其中所述方法包括将CD14 +单核细胞分为朗格汉斯细胞，间质树突状细胞， 或通过在包含上皮细胞和/或间充质细胞的细胞环境的存在下放置CD14 +单核细胞来进入两种类型的细胞。 本发明还涉及包含这种制备的朗格汉斯细胞和/或间质树突状细胞，以及任选的巨噬细胞和内皮细胞的细胞或组织模型，以及这种细胞或组织模型的用途。

公开(公告)号：US5672301A

公开(公告)日：1997-09-30

申请号：US387774

申请日：1995-02-21

Applicant: Isabelle Orly ,  Marie-Christine Levy ,  Eric Perrier

Inventor： Isabelle Orly ,  Marie-Christine Levy ,  Eric Perrier

IPC: A23L29/10 ,  A61J3/07 ,  B01J13/08 ,  B01J13/10 ,  B01J13/12 ,  B01J13/14 ,  B01J13/20 ,  B01J13/02

CPC classification number: B01J13/206 ,  B01J13/08 ,  B01J13/10

Abstract: The method for producing microparticles is characterized in that it comprises the following steps: preparation of an emulsion of a solution of a substance or a mixture of substances in a dispersing liquid wherein said substance or said mixture are substantially insoluble; incorporating to said dispersed phase a chemical agent substantially insoluble in the dispersing liquid so as to cause within the dispersed phase a chemical or physicochemical reaction responsible for the formation of microparticles which are then isolated.

Abstract translation: PCT No.PCT / FR93 / 00791 Sec。 371日期1995年2月21日 102（e）1995年2月21日PCT PCT 1993年8月4日PCT公布。 公开号WO94 / 04260 日期：1994年3月3日该微粒的制造方法的特征在于，其包括以下步骤：将物质或物质的混合物的溶液的乳液制备在分散液中，其中所述物质或所述混合物基本上不溶; 向所述分散相中加入基本上不溶于分散液体的化学试剂，以便在分散相内引起负责形成微粒的化学或物理化学反应，然后分离。

公开(公告)号：US09308161B2

公开(公告)日：2016-04-12

申请号：US13455366

申请日：2012-04-25

Applicant: Charbel Bouez ,  Claudine Gleyzal ,  Isabelle Orly ,  Valerie Andre ,  Pascal Sommer ,  Corinne Reymermier ,  Odile Damour ,  Eric Perrier

Inventor： Charbel Bouez ,  Claudine Gleyzal ,  Isabelle Orly ,  Valerie Andre ,  Pascal Sommer ,  Corinne Reymermier ,  Odile Damour ,  Eric Perrier

IPC: A61K36/00 ,  A61K8/97 ,  A61K36/17 ,  A61K36/185 ,  A61K36/48 ,  A61K36/54 ,  A61Q19/00 ,  A61Q19/08 ,  G01N33/50

CPC classification number: A61K8/97 ,  A61K9/0014 ,  A61K36/17 ,  A61K36/185 ,  A61K36/45 ,  A61K36/48 ,  A61K36/54 ,  A61K36/77 ,  A61K2800/596 ,  A61K2800/70 ,  A61Q19/00 ,  A61Q19/004 ,  A61Q19/08 ,  G01N33/5011 ,  A61K2300/00

Abstract: The disclosed substance restores normal co-expression and interaction between the LOX and NRAGE proteins. Particularly, an effective amount of the substance that modulates the expression and/or activity of LOX of SEQ ID NO: 1 and/or that modulates the expression and/or activity of NRAGE of SEQ ID NO: 2, may be used for the manufacture of a composition for modulating the interaction between the LOX and NRAGE proteins to regulate the balance between the cellular phenomena of proliferation, differentiation and apoptosis, particularly in cases where the balance between these phenomena is disturbed, and especially in cases where the interaction between LOX and NRAGE is absent or altered. The invention makes it possible especially to treat and/or prevent skin ageing, lichen planus, graft-versus-host reaction (GVH), eczema, psoriasis and a cancer, particularly an epithelial cancer and more particularly a cutaneous epithelial cancer of basocellular or spinocellular type.

Abstract translation: 所公开的物质恢复LOX和NRAGE蛋白之间的正常共表达和相互作用。 特别地，有效量的调节SEQ ID NO：1的LOX的表达和/或活性的物质和/或调节SEQ ID NO：2的NRAGE的表达和/或活性的物质可用于制造 用于调节LOX和NRAGE蛋白之间相互作用的组合物，以调节增殖，分化和凋亡的细胞现象之间的平衡，特别是在这些现象之间的平衡受到干扰的情况下，特别是在LOX和 NRAGE不存在或改变。 本发明可以特别地治疗和/或预防皮肤老化，扁平苔藓，移植物抗宿主反应（GVH），湿疹，牛皮癣和癌症，特别是上皮癌，特别是基底细胞或脊髓细胞的皮肤上皮癌 类型。

公开(公告)号：US20120225141A1

公开(公告)日：2012-09-06

申请号：US13455366

申请日：2012-04-25

Applicant: Charbel Bouez ,  Claudine Gleyzal ,  Isabelle Orly ,  Valerie Andre ,  Pascal Sommer ,  Corinne Reymermier ,  Odile Damour ,  Eric Perrier

Inventor： Charbel Bouez ,  Claudine Gleyzal ,  Isabelle Orly ,  Valerie Andre ,  Pascal Sommer ,  Corinne Reymermier ,  Odile Damour ,  Eric Perrier

IPC: A61K36/00 ,  A61K36/752 ,  A61P43/00 ,  A61P37/06 ,  A61P37/08 ,  A61K36/736 ,  A61K36/31

CPC classification number: A61K8/97 ,  A61K9/0014 ,  A61K36/17 ,  A61K36/185 ,  A61K36/45 ,  A61K36/48 ,  A61K36/54 ,  A61K36/77 ,  A61K2800/596 ,  A61K2800/70 ,  A61Q19/00 ,  A61Q19/004 ,  A61Q19/08 ,  G01N33/5011 ,  A61K2300/00

Abstract: The disclosed substance restores normal co-expression and interaction between the LOX and NRAGE proteins. Particularly, an effective amount of the substance that modulates the expression and/or activity of LOX of SEQ ID NO: 1 and/or that modulates the expression and/or activity of NRAGE of SEQ ID NO: 2, may be used for the manufacture of a composition for modulating the interaction between the LOX and NRAGE proteins to regulate the balance between the cellular phenomena of proliferation, differentiation and apoptosis, particularly in cases where the balance between these phenomena is disturbed, and especially in cases where the interaction between LOX and NRAGE is absent or altered. The invention makes it possible especially to treat and/or prevent skin ageing, lichen planus, graft-versus-host reaction (GVH), eczema, psoriasis and a cancer, particularly an epithelial cancer and more particularly a cutaneous epithelial cancer of basocellular or spinocellular type.

Abstract translation: 所公开的物质恢复LOX和NRAGE蛋白之间的正常共表达和相互作用。 特别地，有效量的调节SEQ ID NO：1的LOX的表达和/或活性的物质和/或调节SEQ ID NO：2的NRAGE的表达和/或活性的物质可用于制造 用于调节LOX和NRAGE蛋白之间相互作用的组合物，以调节增殖，分化和凋亡的细胞现象之间的平衡，特别是在这些现象之间的平衡受到干扰的情况下，特别是在LOX和 NRAGE不存在或改变。 本发明可以特别地治疗和/或预防皮肤老化，扁平苔藓，移植物抗宿主反应（GVH），湿疹，牛皮癣和癌症，特别是上皮癌，特别是基底细胞或脊髓细胞的皮肤上皮癌 类型。

公开(公告)号：US20110223264A1

公开(公告)日：2011-09-15

申请号：US12091768

申请日：2006-10-26

Applicant: Charbel Bouez ,  Claudine Gleyzal ,  Isabelle Orly ,  Valerie Andre ,  Pascal Sommer ,  Corinne Reymermier ,  Odile Damour ,  Eric Perrier

Inventor： Charbel Bouez ,  Claudine Gleyzal ,  Isabelle Orly ,  Valerie Andre ,  Pascal Sommer ,  Corinne Reymermier ,  Odile Damour ,  Eric Perrier

IPC: A61K36/736 ,  A61K36/45 ,  A61K36/482 ,  A61K36/185 ,  A61K36/90 ,  A61K36/235 ,  A61K36/17 ,  A61K36/48 ,  A61K36/36 ,  A61K36/42 ,  A61K36/54 ,  A61K36/752 ,  A61K31/22 ,  A61K31/734 ,  A61K36/23 ,  A61K36/14 ,  A61K36/282 ,  A61K36/31 ,  A61P17/00 ,  A61Q19/00

CPC classification number: A61K8/97 ,  A61K9/0014 ,  A61K36/17 ,  A61K36/185 ,  A61K36/45 ,  A61K36/48 ,  A61K36/54 ,  A61K36/77 ,  A61K2800/596 ,  A61K2800/70 ,  A61Q19/00 ,  A61Q19/004 ,  A61Q19/08 ,  G01N33/5011 ,  A61K2300/00

Abstract: The invention relates to a substance for restoring normal co-expression and interaction between the LOX and NRAGE proteins.The invention relates in particular to the use of an effective amount of at least one substance that modulates the expression and/or activity of LOX of sequence ID no. 1, and/or that modulates the expression and/or activity of NRAGE of sequence ID no. 2, for the manufacture of a composition for modulating the interaction between the LOX and NRAGE proteins in order to regulate the balance between the cellular phenomena of proliferation, differentiation and apoptosis, particularly in cases where the balance between these phenomena is disturbed, and especially in cases where the interaction between LOX and NRAGE is absent or altered.The invention makes it possible especially to treat and/or prevent skin ageing, lichen planus, graft-versus-host reaction (GVH), eczema, psoriasis and a cancer, particularly an epithelial cancer and more particularly a cutaneous epithelial cancer, of basocellular or spinocellular type.

Abstract translation: 本发明涉及用于恢复LOX和NRAGE蛋白质正常共表达和相互作用的物质。 本发明特别涉及使用有效量的至少一种调节序列ID号LOX的表达和/或活性的物质。 1和/或其调节序列ID号NRAGE的表达和/或活性。 2，为了制备用于调节LOX和NRAGE蛋白质之间的相互作用的组合物，以调节增殖，分化和细胞凋亡的细胞现象之间的平衡，特别是在这些现象之间的平衡受到干扰的情况下，特别是在 LOX和NRAGE之间的相互作用不存在或改变的情况。 本发明使得可能特别地治疗和/或预防皮肤老化，扁平苔藓，移植物抗宿主反应（GVH），湿疹，牛皮癣和癌细胞，特别是上皮癌，更特别是皮肤上皮癌的基质细胞或 脊柱细胞型。

公开(公告)号：US5658593A

公开(公告)日：1997-08-19

申请号：US594479

申请日：1996-01-31

Applicant: Isabelle Orly ,  Alain Huc

Inventor： Isabelle Orly ,  Alain Huc

IPC: A61F2/00 ,  A61L27/24 ,  A61L27/26 ,  A61L27/46 ,  A61L27/50 ,  A61L31/04 ,  A61K9/50

CPC classification number: A61L31/044 ,  A61L27/24 ,  A61L27/26 ,  A61L27/46 ,  A61L27/50 ,  A61F2310/00365 ,  A61L2400/06 ,  Y10T428/2989

Abstract: A collagen-based composition including microcapsules of atelocollagen or of a mixture of atelocollagen and a polysaccharide, particularly glycosaminoglycan, suspended in a viscous biocompatible carrier solution. Together, the microcapsules and the viscous carrier solution preferably have a viscosity such that the composition may be injected, in particular as a continuous thread from a needle. Said composition is readily injectable and may be used as a soft or bony tissues filling material for, or as a system for the controlled delivery and release of biologically, cosmetically or pharmaceutically active substances.

Abstract translation: 一种基于胶原的组合物，其包含悬浮在粘性生物相容性载体溶液中的胶原蛋白的微胶囊或者胶原蛋白和多糖的混合物，特别是糖胺聚糖。 一起，微胶囊和粘性载体溶液优选具有这样的粘度，使得组合物可以特别地作为来自针的连续丝注入。 所述组合物是易于注射的，并且可以用作柔软或骨组织填充材料，或用作用于控制递送和释放生物学美容或药学活性物质的系统。

公开(公告)号：US20100297765A1

公开(公告)日：2010-11-25

申请号：US12851592

申请日：2010-08-06

Applicant: Nicolas Bechetoille ,  Valerie Andre ,  Isabelle Orly ,  Eric Perrier

Inventor： Nicolas Bechetoille ,  Valerie Andre ,  Isabelle Orly ,  Eric Perrier

IPC: C12N5/0784 ,  C12N5/0786

CPC classification number: C12N5/0639 ,  C12N5/064 ,  C12N5/0697 ,  C12N5/0698 ,  C12N2502/091 ,  C12N2502/094 ,  C12N2502/097 ,  C12N2502/1121 ,  C12N2502/1323 ,  C12N2502/243 ,  C12N2502/28 ,  C12N2503/06

Abstract: The present invention relates to a method for preparing Langerhans cells or interstitial dendritic cells or both from CD14+ monocytes stemming from the peripheral circulatory blood of a living being, wherein the method comprises differentiation of CD 14+ monocytes into either Langerhans cells, interstitial dendritic cells, or into both types of cells by placing the CD14+ monocytes in the presence of a cell environment comprising epithelial cells and/or mesenchymatous cells.The present invention also relates to cell or tissue models comprising such prepared Langerhans cells and/or interstitial dendritic cells, and optionally macrophages and endothelial cells, and to the uses of such cell or tissue models.

Abstract translation: 本发明涉及一种从活体的外周循环血中产生的CD14 +单核细胞或两者从朗姆汉斯细胞或间质树突状细胞制备的方法，其中所述方法包括将CD14 +单核细胞分为朗格汉斯细胞，间质树突状细胞， 或通过在包含上皮细胞和/或间充质细胞的细胞环境的存在下放置CD14 +单核细胞来进入两种类型的细胞。 本发明还涉及包含这种制备的朗格汉斯细胞和/或间质树突状细胞，以及任选的巨噬细胞和内皮细胞的细胞或组织模型，以及这种细胞或组织模型的用途。

公开(公告)号：US20080089906A1

公开(公告)日：2008-04-17

申请号：US11803805

申请日：2007-05-16

Applicant: Delphine Rival ,  Sebastien Bonnet ,  Isabelle Orly ,  Eric Perrier

Inventor： Delphine Rival ,  Sebastien Bonnet ,  Isabelle Orly ,  Eric Perrier

IPC: A61K8/97 ,  A61K36/00 ,  A61K36/03 ,  A61K36/31 ,  A61P17/00 ,  G01N33/53 ,  A61Q19/00 ,  A61K36/815 ,  A61K36/8888 ,  A61K36/8998

CPC classification number: A61K8/97 ,  A61K36/185 ,  A61K36/31 ,  A61K36/8998 ,  A61K2800/91 ,  A61Q1/06 ,  A61Q5/02 ,  A61Q19/00 ,  A61Q19/04 ,  A61Q19/08 ,  A61Q19/10 ,  G01N33/557 ,  G01N2333/503 ,  G01N2500/04

Abstract: The invention relates to substances which are capable of protecting FGF-2, to a composition for preventing or controlling degradation of FGF-2, and a method of protecting FGF-2 in the skin from degradation.In particular, the invention relates to an extract of Hibiscus Abelmoschus or ambrette, a rebokza extract, a gougizi berry extract, a banha extract, a lessonia extract, a mustard flour extract, a wooyin extract, a barley extract, and/or a sesame extract, in amounts effective to protect FGF-2 from its degradation.Further, the present invention allows the extracellular matrix to be restructured, particularly at the dermis, which is useful, for example, for controlling aging.

Abstract translation: 本发明涉及能够保护FGF-2的物质，用于预防或控制FGF-2降解的组合物，以及保护皮肤中FGF-2的降解方法。 特别地，本发明涉及芙蓉芙蓉提取物或胭脂红提取物，雷贝提取物，甘草提取物，巴拿马提取物，皂甙提取物，芥子提取物，维生素提取物，大麦提取物和/或芝麻的提取物。 提取物，有效保护FGF-2免于其降解。 此外，本发明允许细胞外基质重组，特别是在真皮上，其可用于例如控制老化。

公开(公告)号：US20100272699A1

公开(公告)日：2010-10-28

申请号：US12663015

申请日：2008-06-06

Applicant: Sabine Pain ,  Colette Dezutter ,  Valerie Aandre ,  Corinne Reymermier ,  Isabelle Orly ,  Eric Perrier

Inventor： Sabine Pain ,  Colette Dezutter ,  Valerie Aandre ,  Corinne Reymermier ,  Isabelle Orly ,  Eric Perrier

IPC: A61K36/06 ,  A61K36/00 ,  A61K36/889 ,  A61K36/736 ,  A61K36/752 ,  A61K36/11 ,  A61P17/00

CPC classification number: A61K36/14 ,  A61K8/97 ,  A61K8/99 ,  A61K31/216 ,  A61K31/343 ,  A61K31/437 ,  A61K36/185 ,  A61K36/24 ,  A61K36/28 ,  A61K36/48 ,  A61K36/53 ,  A61K36/736 ,  A61K36/752 ,  A61K36/888 ,  A61K36/90 ,  A61Q19/08

Abstract: The invention concerns active substances modulating the expression of the receptors of the products of the POMC gene (MC-IR, MC-2R, and the μ opioid receptor), and possibly modulating the expression of POMC in cutaneous cells, notably to modulate the proliferation and differentiation of epidermal cells in order to re-epithelial, maintain innervation, irrigate the skin, or to fight against aging, or to modulate pigmentation independently or not of cutaneous aging. The invention also concerns a method of screening such active substances.

Abstract translation: 本发明涉及调节POMC基因（MC-IR，MC-2R和μ阿片受体）产物受体表达的活性物质，并且可能调节皮肤细胞中POMC的表达，特别是调节增殖 和表皮细胞的分化以重新上皮，维持神经支配，灌洗皮肤或抵抗衰老，或独立地调节色素沉着或不是皮肤老化。 本发明还涉及筛选这种活性物质的方法。